Wedbush Downgrades Alto Neuroscience to Neutral, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has downgraded Alto Neuroscience (NYSE:ANRO) from Outperform to Neutral and significantly lowered the price target from $29 to $4.
October 23, 2024 | 3:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wedbush has downgraded Alto Neuroscience from Outperform to Neutral, with a drastic reduction in the price target from $29 to $4, indicating a negative outlook.
The downgrade from Outperform to Neutral by a reputable analyst like Wedbush, along with a significant reduction in the price target, suggests a negative short-term outlook for Alto Neuroscience. This is likely to impact investor sentiment and could lead to a decrease in the stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100